> 40 percent of low-risk prostate cancer patients were getting inappropriate imaging tests

A new paper in JAMA Oncology has shown that between 2004 and 2007 nearly 45 percent of men initially diagnosed with low-risk prostate cancer were receiving unnecessary bone scans and CT scans in some regions of the USA. … READ MORE …

Use of bisphosphonate therapy in men on ADT in Ontario, Canada

According to a research letter published in the Journal of the American Medical Association, most men in Ontario, Canada, who have androgen deprivation therapy (ADT) for treatment of prostate cancer have not been receiving bisphosphonate or comparable therapy. … READ MORE …

Can the “bone scan index” act as a surrogate marker for survival?

One of the problems with clinical trials for late-stage prostate cancer today is that we commonly need to follow all patients until death before we can collect sufficiently accurate data to be certain that a particular product is or is not effective in extending patient survival. … READ MORE …

Potential new imaging test for metastatic prostate cancer

According to a newly published study in the journal Cancer Research, a collaborative research team at the Massey Cancer Center of Virgina Commonwealth University and at Johns Hopkins has developed a new, systemically administered, non-invasive, molecular-genetic technique to image bone metastases resulting from prostate cancer. … READ MORE …

Single- vs. multi-fraction radiation therapy for metastatic, bone-related cancer pain

Data published in 2005 and later have clearly shown that — for most patients — single-fraction radiation therapy (e.g., a single dose of 8 Gy) is better than multi-fraction radiation therapy (e.g., 30 Gy given over 10 treatments) for the treatment of bone pain consequent to metastatic cancer that has spread into the bones (in prostate cancer and other forms of cancer). … READ MORE …

Use of imaging tests in low-risk prostate cancer — striking the right balance

An article published a couple of weeks ago in the Journal of the National Cancer Institute looks at the effects of a physician education campaign in Sweden to reduce the inappropriate use of bone scans and other imaging tests among men with an initial diagnosis of low-risk prostate cancer. … READ MORE …

Prevention of bone-related and metabolic complications of treatment for men on ADT

A new article from an Australian clinical research group in the journal Andrology addresses “the effectiveness of implementing standardized guidelines to mitigate metabolic and bone side effects of androgen deprivation therapy (ADT) in men with non-metastatic prostate cancer.” … READ MORE …